Cargando…
Response to Treatment with TNFα Inhibitors in Rheumatoid Arthritis Is Associated with High Levels of GM-CSF and GM-CSF(+) T Lymphocytes
Biologic TNFα inhibitors are a mainstay treatment option for patients with rheumatoid arthritis (RA) refractory to other treatment options. However, many patients either do not respond or relapse after initially responding to these agents. This study was carried out to identify biomarkers that can d...
Autores principales: | Bystrom, Jonas, Clanchy, Felix I., Taher, Taher E., Al-Bogami, Mohammed M., Muhammad, Hawzheen A., Alzabin, Saba, Mangat, Pamela, Jawad, Ali S., Williams, Richard O., Mageed, Rizgar A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5597702/ https://www.ncbi.nlm.nih.gov/pubmed/28488248 http://dx.doi.org/10.1007/s12016-017-8610-y |
Ejemplares similares
-
Pharmacodynamic biomarkers and differential effects of TNF‐ and GM‐CSF‐targeting biologics in rheumatoid arthritis
por: Guo, Xiang, et al.
Publicado: (2018) -
Harnessing the Therapeutic Potential of Th17 Cells
por: Bystrom, Jonas, et al.
Publicado: (2015) -
GM-CSF in inflammation
por: Hamilton, John A.
Publicado: (2019) -
The efficacy and safety of targeting GM-CSF in arthritis
por: Bykerk, Vivian P
Publicado: (2020) -
G-CSF and GM-CSF in clinical trials.
por: Antman, K. H.
Publicado: (1990)